By David S. MacDougall
GOTHENBURG, Sweden -- October 17, 2010 -- Walking and mobility problems commonly develop within the first 2 years following a diagnosis of multiple sclerosis (MS), according to finding s presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
At 2 years post diagnosis and beyond, the proportion of patients with MS reporting moderate or severe walking and mobility problems continues to increase.
MS is often accompanied by functional impairment due to mobility problems, and these are strongly related to a decreased health-related quality of life (HR-QOL). The timeframe for the development of walking and mobility problems in patients with MS and their progression following MS diagnosis have not been well characterised.
The study group was drawn from the Adelphi MS Disease Specific Programme, a cross-sectional study of 340 European neurologists. Participating neurologists completed detailed patient records for a total of 3,505 patients with MS.
A group of 1,887 patients with MS completed questionnaires about their disease diagnosis, HR-QOL, and symptoms, including the presence and severity of walking and mobility problems noted lead author Krithika Rajagopalan, PhD, Biogen Idec, Cambridge, Massachusetts, reporting results here at a presentation on October 15.
GOTHENBURG, Sweden -- October 17, 2010 -- Walking and mobility problems commonly develop within the first 2 years following a diagnosis of multiple sclerosis (MS), according to finding s presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
At 2 years post diagnosis and beyond, the proportion of patients with MS reporting moderate or severe walking and mobility problems continues to increase.
MS is often accompanied by functional impairment due to mobility problems, and these are strongly related to a decreased health-related quality of life (HR-QOL). The timeframe for the development of walking and mobility problems in patients with MS and their progression following MS diagnosis have not been well characterised.
The study group was drawn from the Adelphi MS Disease Specific Programme, a cross-sectional study of 340 European neurologists. Participating neurologists completed detailed patient records for a total of 3,505 patients with MS.
A group of 1,887 patients with MS completed questionnaires about their disease diagnosis, HR-QOL, and symptoms, including the presence and severity of walking and mobility problems noted lead author Krithika Rajagopalan, PhD, Biogen Idec, Cambridge, Massachusetts, reporting results here at a presentation on October 15.
***********************************************************
"Providing You with 'MS Views and News', is what we do"
Keep Informed and up-to-date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
1 comments:
Eventhough, for the last 2 years i've been using interferone 1b, still my walking is very bad and balance gone!
Post a Comment